Citations

Showing 10 of 108104 citations.

Azygous Anterior Cerebral Artery Acute Occlusion Managed With Endovascular Mechanical Thrombectomy: 2-Dimensional Operative Video
Rangel-Castilla, Leonardo , Siddiqui, Adnan H. , Siddiqui, Adnan H

Mayo Clinic

Operative Neurosurgery | July 27, 2018 | Volume: 16 | Issue: 4 | Pages: 514-515

10.1093/ons/opy183 | PMID 30060127 Get It

Abstract Mechanical thrombectomy has become the standard of care for management of most acute large-vessel occlusion (LVO) strokes. Most intracranial occlusions are located in the middle cerebral and internal carotid arteries. We present a unique case of acute occlusion of an azygous anterior cerebral artery (ACA). A 59-yr-old man with known hypertension and alcoholism presented with right hemiparesis, right facial palsy, aphasia, and dysarthria. His initial National Institutes of Health Stroke Scale (NIHSS) score was 20. Computed tomographic angiography and perfusion imaging demonstrated acute bilateral ACA occlusion with viable penumbra and preserved cerebral blood volume. The patient was not a candidate for intravenous tissue plasminogen activator because he presented with a wake-up stroke. After consent was obtained from his family, the patient was taken urgently for endovascular recanalization. Digital subtraction angiography confirmed acute azygous ACA occlusion. Under conscious sedation, the patient underwent mechanical thrombectomy with a stent retriever and a large-bore aspiration catheter. Successful revascularization (thrombolysis in cerebral infarction [TICI] grade 3) of the azygous ACA and both A2 arteries was obtained after 2 attempts and the use of a different stent retriever (first a 3 × 30 mm Trevo [Stryker Neurovascular, Kalamazoo, Michigan] and then a 4 × 40 mm Solitaire Platinum [Medtronic, Dublin, Ireland]). A reperfusion catheter was used during both attempts. No procedure-related complications occurred. The patient was discharged to a rehabilitation facility 3 d after the procedure with an NIHSS score of 2. In this video, we present the operative nuances of an uncommon location of LVO and its endovascular management.
Commentary: Utilization Trends of Cervical Disk Replacement in the United States
Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Ubl, Daniel S. , Meyer, Jenna , Currier, Bradford L. , Bydon, Mohamad , Alvi, Mohammed Ali , Goyal, Anshit , Habermann, Elizabeth B.

Mayo Clinic

Operative Neurosurgery | July 27, 2018 | Volume: 15 | Issue: 4 | Pages: 40-43

10.1093/ons/opy181 | PMID 30060145 Get It

Primary medial femoral condyle vascularized bone graft for scaphoid nonunions with carpal collapse and proximal pole avascular necrosis
Kollitz, Kathleen M. , Pulos, Nicholas , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Journal of Hand Surgery (European Volume) | July 27, 2018 | Volume: 44 | Issue: 6 | Pages: 600-606

10.1177/1753193418789329 | PMID 30049241 Get It

This study aimed to determine the outcome of free vascularized medial femoral condyle bone grafts in the primary treatment of scaphoid nonunions with scaphoid foreshortening or carpal collapse and intraoperatively documented avascular necrosis. Thirty-two patients (28 male, four female) met the inclusion criteria. Median time from injury to surgery was 70 weeks. Thirty of 32 patients healed at a median of 12 weeks. There was significant improvement from preoperative to postoperative lateral intrascaphoid angle, scapholunate angle, and radiolunate angle. Two scaphoids failed to unite; one patient underwent scaphoidectomy and four-corner fusion 15 months postoperatively after suffering a subsequent injury. Another patient underwent 1,2-intercompartmental supraretinacular artery-based vascularized bone grafting at 4 months postoperatively and then scaphoid excision with four-corner fusion 4 years later. The free vascularized medial femoral condyle bone graft restores scaphoid vascularity and architecture while promoting union in a subset of scaphoid nonunions that has historically been a clinical challenge. Level of evidence: IV
Automated Coagulation Factor Assays Using A Thrombin Specific Chromogenic Substrate
Duncan, Alexander , Bowie, Ejw, Owen, C. A. , Duncan, A

Mayo Clinic

Thrombosis and Haemostasis | July 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652929 Get It

An automated method for specific factor assays has been developed using a novel thrombin-specific chromogenic substrate (developed by A. Aiyappa, Ph. D., Abbott Labs). For factors VIII, IX, XI and XII, the test system includes an ellagic acid activator and brain phospholipid in a calcium containing tris buffer pH 7.4. These are mixed with a plasma sample consisting of a mixture of specific factor deficient substrate and test plasma for 5 minutes and then the chromogenic substrate is added. After another 5 minutes the increase in optical density ΔOD is recorded. Normal plasma serially diluted in specific factor deficient substrate is used to construct a standard graph and test plasma results are interpolated from this.Fifty-four comparative assays have been done for factors VIII and IX and correlated with the results obtained from conventional clotting assays. For factor VIII the correlation coefficient (r)=0.935 (N=35) and for factor IX r=0.941 (N=19). While insufficient data exists to date for factors XI and XII, these assays appear to be comparable to the VIII and IX results.The assays for factors V, VII and X use a simplified system in that the chromogenic substrate and phospholipid are added together. The ΔOD is again recorded after 5 minutes. Test plasma results are interpolated from a standard graph constructed using serially diluted normal plasma as before. To date only the factor V assay has enough data to do a correlation with the clotting assays and r=0.953 (N=13) which is similar to the r value for the VIII and IX assays.Because of the widespread availability of the automated analyzer used in the assay and the standardization of end point determination it provides, specific factor assays might be made more widely available outside specialized coagulation centers.
Systemic Thromboemboli In Mitral Starr-Edwards Prosthesis: A Long-Term Followup (10-19 Years)
Chesebro, James H., Fuster, Valentı́n

Mayo Clinic

Thrombosis and Haemostasis | July 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652858 Get It

The study comprised 170 consecutive patients (pts) seen at Mayo Clinic between 1962 and 1970 who underwent mitral valve replacement with Starr-Edwards prosthesis (model 6000 in 35% of pts, model 6120 in 65% of pts) because of significant chronic mitral incompetence (functional Class III-IV). All patients were on oral anticoagulants and were followed until January 1980 with a followup of 10 to 19 years (yrs) (median 15 yrs). We analyzed (1) the cumulative incidence of systemic emboli, their location and whether or not they left residual deficit; and (2) possible risk factors that might have been predictive, including in the analysis: age, sex, functional class, presence or absence of atrial fibrillation, degree of cardiomegaly, type of prosthesis and degree of anticoagulation.At 12 yrs of followup, 48% of pts had at least one episode of emboli (among these pts, 12% had two episodes); the rate of emboli was maximal within 1 yr postoperatively but persisted over the total followup at a rate of about 3% per yr. Of all emboli, 94% occurred in the cerebral circulation and 66% left neurological deficit. Regarding predictive factors, the incidence of emboli was slightly higher in pts with the prosthesis model 6000 (p<0.05) and in pts considered to be poorly anticoagulated (p<0.05).This unique long-term followup study on pts with mitral Starr-Edwards prosthesis reveals that systemic emboli is a persistent and significant problem. Preliminary data indicates that the addition of a platelet inhibitor to the oral anticoagulant may be beneficial.
Serial Platelet Survival Half-Life (PS) In Peripheral Vascular Disease And Diabetes Mellitus
Kazmier, F J, Chesebro, J H, O'Fallon, JR, Palumbo, P J, Fuster, Vicente Pascual

Mayo Clinic

Thrombosis and Haemostasis | July 27, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652857 Get It

Mayo Clinic, Mayo Foundation, Rochester, MinnesotaPlatelets are believed to play an important role in the pathogenesis of atherosclerosis and thrombotic occlusive arterial disease. As part of a prospective study of peripheral occlusive arterial disease in diabetes mellitus, platelet survival half-life (PS) was determined in years 1 and 2 from the disappearance pattern of 51cr-labeled platelets obtained by measuring radioactivity in serial samples over 8 days in four groups of patients age 50-70. Using computer assisted least-square analysis, a single exponent is fitted to the data and half-life determined.Groups included (1) normal subjects (NC); (2) subjects with clinical and objective evidence (transcutaneous doppler ultrasound and treadmill exercise) of peripheral arterial occlusive disease (AS0); (3) subjects with diabetes mellitus without AS0 (DM); (A) subjects with both diabetes mellitus and AS0 (DM+AS0). 112 subjects were tested in year 1 and 75 of these were available for retesting in year 2.In year 1, there is a difference in the distribution of platelet survival (PS) for the four groups (p=.002). PS is significantly short in groups AS0 and DM+AS0 compared with controls (NC), Year 2 values for PS (75 subjects) were compared to year 1. Using the t test on mean differences PS for each group was not significantly different year 2 vs year 1; mean percent differences year 2 vs year 1 were 1.2% (NC), 0.2% (ASO), 3.2% (DM), and -9.3% (9-3% lower than year 1 for DM+ ASO).Platelet survival half-life (PS) does distinguish popula tion groups and is reproducible when repeated.
Blood Group (BG) Prevalence In End-Stage (ES) Renal Disease (RD): Relationship To Ristocetin Willebrand Factor (VIII: RWF) And Platelet Survival (PS)
Moore, Beverley A. , Donadio, JamesV., Kazmier, F J, Bowie, Ejw, Torres, V, Fuster, Valentı́n , Moore, B

Mayo Clinic

Thrombosis and Haemostasis | July 26, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652983 Get It

BG 0 patients (pts) have lower risk for cardiovascular-thromboembolic disease than A-AB-B pts, particularly males. This might be related to blood hypocoagulability (lower Factor VIII). We report BG frequencies in our Caucasian renal transplant population divided in two groups, ES reflux nephropathy (RN) and ESRD of other etiologies excluding diabetes mellitus.BG 0 male pts are protected, especially for ESRN. To determine whether this sex dependency could be related to different VIII: RWF levels or PS, VIII:RWF levels (n=82) and 51Cr-labelled PS (n=74) were analyzed in controls according to sex and BG.VIII: RWF is sex independent and lower in BG 0. PS is BG independent and shortened in males. A hypercoagulable State reflected by high VIII: RWF and short PS might explain the increased risk of non-BG 0 males to develop ESRD. Non-BG 0 male pts with RN may be more susceptible to develop progressive RD.
Platelet Deposition In Extracardiac Conduits In Humans: A Noninvasive Quantification
Agarwal, Kishan C., Dewanjee, Mrinal K., Wahner, Heinz W., Robertson, James S., Brown, J H, Chesebro, J H, Kaye, M. P., Puga, Francisco J., Danielson, Gordon K., Fuster, Valentı́n , Feldt, Robert

Mayo Clinic

Thrombosis and Haemostasis | July 26, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652942 Get It

In right-sided extracardiac conduits inserted for surgical correction of certain congenital heart defects, obstruction is a significant late complication requiring conduit replacement in about 5% of the patients. Our histopathologic study indicates a significant role of platelets in the pathogenesis. This study was designed to evaluate the feasibility of imaging procedure with 111-Indium-labeled platelets to localize and later quantify platelet accumulation in the conduits. Four patients with pulmonary atresia and 1 with truncus arteriosus underwent conduit placement, 2 with and 3 without porcine valve. Autologous platelets collected.from 43 ml of blood drawn prior to surgery were labeled with 111-Indium-oxine in ACD-saline medium (labeling efficiency 50-60%). 400-500 μCi of autologous 111-Indium-labeled platelets were administered intravenously immediately after surgery in 4, and five days after surgery in 1 patient. Imaging was performed at 6 hours and daily for 1-4 days using a portable gamma camera interfaced with a computer and fitted with medium-energy parallel hole collimator. Platelet deposition was noted at the site of the conduit in all 5 patients. Maximum accumulation (0.1-0.3% of dose) of platelets was seen within the first 24 hours. Activity over blood pool and lungs declined and over liver and spleen increased in a predictable manner over the imaging period. This technique has potential use as a noninvasive quantitative tool to study the effect of platelet inhibitor drugs in preventing conduit obstruction.
Quantitation Of Platelet Lysis, Platelet Consumption On Oxygenator And Stabilization Of Platelet Membrane With Prostacyclin And Ibuprofen During Cardiopulmonary Bypass Surgery In Dogs
Dewanjee, Mrinal K., Vogel, S R, Kaye, Michael P., Peterson, Kevin

Mayo Clinic

Thrombosis and Haemostasis | July 26, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652777 Get It

Prostacyclin (PGI2) and Ibuprofen (IP) may preserve platelet integrity and function during cardiopulmonary bypass (CPB). Platelet consumption on bubble and membrane oxygenator, platelet lysis, and platelet microembolism were studied in 7 control, 6 PGI2-, and 5 IP-treated dogs undergoing CPB. At 18 hours after I.V. administration of autologous In-Ill-labeled platelets (300 μCi), 7 heparinized dogs (300 u/kg), and 6 dogs treated with I.V. infusion of PGI2 (25 ng/kg/min) and heparin (100 u/kg), and 5 dogs with I.V. IP (12.5 mg/kg) 15 min prior to bypass procedure underwent CPB for 1 hour. In-111 in plasma obtained from platelet lysis was determined by centrifugation at 200,000 G of serial blood samples at 5-min intervals during CPB. Hemodilution was measured with I-125-labeled serum albumin (10 μCi). Platelet deposition on oxygenator was imaged with a gamma camera and quantitated with an ionization chamber. An insignificant amount of platelet (<0.2%) was found in the heat exchanger. In-111-labeled platelet level in blood of control dogs 20 min after CPB initiation decreased to 23 ± 5% of prebypass level, 38 ± 5% in PGI2 group, and 25 ± 5% in the IP group. Plasma In-111 increased to 34±7% in control, 15±5% in PGI2 group, and 17±3% in IP group (p< 0.01). Platelet deposition on the oxygenator amounted to 20±5% of In-111 platelets in control, 11±3% of PGI2, and 13±4% in IP group (p< 0.01). These results indicate that both PGI2 and IP significantly reduce platelet consumption in oxygenator and platelet lysis during CPB. Thus PGI2 may reduce postoperative bleeding. Ibuprofen, although preserving platelet function, has a longer duration of action and, hence, systemic administration prior to CPB is not practical. Surface coating of extracorporeal surfaces with IP might be beneficial.
The impact of fetal endoscopic tracheal occlusion in isolated left‐sided congenital diaphragmatic hernia on left‐sided cardiac dimensions
Dhillon, Gurpreet S. , Maskatia, Shiraz A. , Loar, Robert W. , Colquitt, John L. , Mehollin‐Ray, Amy R. , Belfort, Michael A., Kailin, Joshua A. , Ruano, Rodrigo , Olutoye, Oluyinka O.

Mayo Clinic

Prenatal Diagnosis | July 26, 2018 | Volume: 38 | Issue: 11 | Pages: 812-820

10.1002/pd.5333 | PMID 30047996 Get It

AbstractObjectivesFetal endoscopic tracheal occlusion (FETO) is offered to fetuses with congenital diaphragmatic hernia (CDH) and severe lung hypoplasia to promote lung growth and may secondarily affect left heart growth. The effects of FETO on left heart hypoplasia (LHH) are not described post‐CDH repair.MethodsA retrospective analysis was performed for fetuses with left‐sided CDH who underwent FETO and severity‐matched controls from 2007 to 2016 at our institution. Echocardiographic, ultrasound, and MRI data were reviewed. Left heart dimensions were assessed prenatally and postnatally. Primary clinical outcome evaluated was death.ResultsTwelve FETO patients and 18 controls were identified. Fetal LHH was noted in both groups and worsened after FETO. Postnatal mitral valve dimensions were larger in the FETO group pre‐CDH repair (P = .03). Post‐CDH repair, mitral valve and left ventricular dimensions were not significantly different between groups (P = .79 and P = .63 respectively) while FETO aortic valve dimensions were smaller (P = .04). Extracorporeal membrane oxygenation use was lower in the FETO group. No associations were found between left heart dimensions and outcomes.ConclusionAlthough increased lung growth was seen after FETO, fetal LHH persisted with relative normalization seen post‐repair. Persistent LHH post‐FETO could be secondary to a small contribution of pulmonary venous return to the fetal left heart and increased intrathoracic pressures post‐FETO.